Prescription Justice
BLOG POSTS

18
Feb
2021
#
In the world of prescription drug prices, it's a new dawn, it's a new day, it's a new life - or is it?
Read More
21
Oct
2020
#
The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL), with a grade of A+. The only other A+ in the House goes to Rep. Perter Welch (D-VT), who landed a score of 99.5.
Read More
07
Oct
2020
#
Rep. Tom Malinowski (D-NJ7) is one of a very small number of members of the U.S. House of Representatives to receive an A- in our Congressional Report Card on Drug Prices. Only 16 other House members received an A-, A or A+. The congressman’s high grade is based on his voting record and because he has taken the Prescription Justice Pledge, proclaiming support for the Prescription Justice Policy Platform on lowering drug prices. We applaud Rep. Malisnowski for his actions to help end the crisis of high drug prices in America!
Read More
24
Sep
2020
#
Prescription Justice is pleased to announce that Isaiah Cochran, MD has been appointed to the Prescription Justice Board of Directors. Dr. Cochran is the immediate past president and chair of the board of trustees for the American Medical Student Association (AMSA). He served as a key organizational spokesperson for AMSA and as an active promoter of the organization's educational programming, advocacy pursuits, and membership recruitment and engagement efforts.
Read More
17
Sep
2020
#
Prescription Justice has graded all members of Congress in a drug prices report card. Some people are dismayed that Speaker Nancy Pelosi received an F. After all, didn’t she roll-out and shepherd H.R. 3, the Elijah Cummings Lower Drug Costs Now Act, through the House and vociferously called for its passage on the House floor, as read on the Speaker’s website. So, what happened to her grade? A lot of Rep. Pelosi’s F has to do with her role as Speaker and how it differs from all other legislators.
Read More

Stay informed about news and advocacy centered on the crisis of high drug prices